BerandaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$4,32
Rentang hari
$4,32 - $4,70
Rentang tahun
$3,32 - $12,70
Kapitalisasi pasar
178,36 jt USD
Volume Rata-Rata
2,52 rb
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 0,00 | -100,00% |
Biaya operasional | 52,85 jt | 815,93% |
Laba bersih | -11,23 jt | 43,22% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,30 | — |
EBITDA | -14,22 jt | 13,35% |
Tarif pajak efektif | -0,02% | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 149,44 jt | -20,04% |
Total aset | 158,53 jt | -20,08% |
Total liabilitas | 16,89 jt | -22,95% |
Total ekuitas | 141,64 jt | — |
Saham yang beredar | 36,71 jt | — |
Harga terhadap nilai buku | 1,12 | — |
Tingkat pengembalian aset | -23,65% | — |
Tingkat pengembalian modal | -25,90% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -11,23 jt | 43,22% |
Kas dari operasi | -13,20 jt | 17,47% |
Kas dari investasi | -4,49 jt | -123,10% |
Kas dari pembiayaan | 15,30 jt | 5.234,56% |
Perubahan kas bersih | -1,88 jt | -72,29% |
Arus kas bebas | -12,16 jt | -29,92% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
162
